A Nomogram for Identifying HR+/Her2- Breast Cancer Patients with Positive Sentinel Lymph Nodes and Omitted Axillary Lymph Node Dissection Who Need Abemaciclib Therapy

Hanzhao Yang; Yadong Sun; Peili Wang; Jianghua Qiao; Lianfang Li; Zhenduo Lu; Xianfu Sun; Chongjian Zhang; Xiuchun Chen; Min Yan; Shude Cui; Chengzheng Wang; Zhenzhen Liu

doi:10.12659/MSM.940124

16 July 2023 : Clinical Research

A Nomogram for Identifying HR+/Her2- Breast Cancer Patients with Positive Sentinel Lymph Nodes and Omitted Axillary Lymph Node Dissection Who Need Abemaciclib Therapy

Hanzhao Yang^1CDE, Yadong Sun^1BCD, Peili Wang^1BD, Jianghua Qiao^1BC, Lianfang Li^1B, Zhenduo Lu^1B, Xianfu Sun^1B, Chongjian Zhang^1B, Xiuchun Chen^1B, Min Yan^1B, Shude Cui^1B, Chengzheng Wang^1ADF, Zhenzhen Liu^1AE

DOI: 10.12659/MSM.940124

Med Sci Monit 2023; 29:e940124

Authors information Article notes Copyright and License information

Background Material and Methods Results Discussion Conclusions References

Related articles Order reprints Share article Share by email

View HTML version

Figure 3 The DCA curve demonstrates the clinical efficacy of the nomogram. The red line is a nomogram predicting the risk of ≥4 positive nodes in patients. The grey line indicates all patients with ≥4 positive nodes, while the black line indicates no patient with ≥4 positive nodes. This DCA could provide a larger net benefit, with ranges of 5% to 54%. DCA – decision curve analysis. R software 4.1.1 (The R Foundation for Statistical Computing, Austria, Vienna).

Back to the Article

A Nomogram for Identifying HR+/Her2- Breast Cancer Patients with Positive Sentinel Lymph Nodes and Omitted Axillary Lymph Node Dissection Who Need Abemaciclib Therapy

Your Privacy